Zhachong Shisanwei Pill resists ischemic stroke by lysosome pathway based on proteomics and bioinformatics

Song, Qi; Bi, Lei; Jiao, Jiakang; Shang, Jinfeng; Li, Qiannan; Shabuerjiang, Lizha; Bai, Meirong; Liu, Xin

doi:10.1016/j.jep.2022.115766

Cited by 6 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma protein targets have been identified as potential therapeutic targets for IS, 9 and clinical drugs that bind to these proteins and modulate their activity or downstream effects have been approved to halt the disease progression. 10 IS, the main cause of stroke-related mortality and disability, has similar pathological mechanisms to RAO, which is mostly caused by cardioembolic or artery−artery embolism, often involving the ipsilateral carotid artery. 11 Moreover, the two diseases share common risk factors, such as smoking, hypertension, and hyperlipidemia.…”

Section: ■ Introductionmentioning

confidence: 99%

Plasma Proteomics to Identify Drug Targets and Potential Drugs for Retinal Artery Occlusion: An Integrated Analysis in the UK Biobank

Cao,

Zhuang,

Kong

et al. 2024

J. Proteome Res.

View full text Add to dashboard Cite

Retinal artery occlusion (RAO), which is positively correlated with acute ischemic stroke (IS) and results in severe visual impairment, lacks effective intervention drugs. This study aims to perform integrated analysis using UK Biobank plasma proteome data of RAO and IS to identify potential targets and preventive drugs. A total of 7191 participants (22 RAO patients, 1457 IS patients, 8 individuals with both RAO and IS, and 5704 healthy agegender-matched controls) were included in this study. Unique 1461 protein expression profiles of RAO, IS, and the combined data set, extracted from UK Biobank Plasma proteomics projects, were analyzed using both differential expression analysis and elastic network regression (Enet) methods to identify shared key proteins. Subsequent analyses, including single cell type expression assessment, pathway enrichment, and druggability analysis, were conducted for verifying shared key proteins and discovery of new drugs. Five proteins were found to be shared among the samples, with all of them showing upregulation. Notably, adhesion G-protein coupled receptor G1 (ADGRG1) exhibited high expression in glial cells of the brain and eye tissues. Gene set enrichment analysis revealed pathways associated with lipid metabolism and vascular regulation and inflammation. Druggability analysis unveiled 15 drug candidates targeting ADGRG1, which demonstrated protective effects against RAO, especially troglitazone (−8.5 kcal/mol). Our study identified novel risk proteins and therapeutic drugs associated with the rare disease RAO, providing valuable insights into potential intervention strategies.

show abstract

Section: ■ Introductionmentioning

confidence: 99%